



## Final Appraisal Recommendation

### Histamine dihydrochloride (Ceplene<sup>®</sup>▼)

Submission by:  
Meda Pharmaceuticals

Advice No: 0411- April 2011

#### Recommendation of AWMSG

Histamine dihydrochloride (Ceplene<sup>®</sup>▼) is not recommended for use within NHS Wales for maintenance therapy for adult patients with acute myeloid leukaemia in accordance with its licensed indication. The case for clinical effectiveness and cost effectiveness has not been proven.

#### Additional notes:

People who are currently being treated with histamine dihydrochloride (Ceplene<sup>®</sup>▼) for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: